FindTrial
Sign In

CLBR001 and SWI019

COMBINATION_PRODUCT2 trials

Sponsors

Calibr, a division of Scripps Research

Conditions

Burkitt LymphomaChronic Lymphocytic Leukemia (CLL)Diffuse Large B Cell Lymphoma (DLBCL)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Lymphoplasmacytic LymphomaMantle Cell LymphomaMantle Cell Lymphoma (MCL)

Phase 1

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
CompletedNCT04450069
Calibr, a division of Scripps ResearchBurkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B Cell Lymphoma (DLBCL) +9
Start: 2020-08-14End: 2024-05-06Updated: 2024-08-20
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
CompletedNCT04488354
Calibr, a division of Scripps ResearchBurkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL) +9
Start: 2021-01-21End: 2025-10-06Updated: 2026-04-08

Related Papers

First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019)
Blood2021-11-059 citations
IND-Enabling Studies of a Switchable Chimeric Antigen Receptor-T Cell (CLBR001+SWI019) to Support First in Human Clinical Study
Blood2021-11-051 citations